viewAdmedus Ltd

Admedus divesting non-core business; to focus on ADAPT product portfolio

The restructure will enable the company to improve working capital management and reduce cash burn through reduction in headcount.

Australian dollars
Admedus generated $11 million in revenue from its ADAPT products in 2018

Admedus Ltd (ASX:AHZ) has entered into an agreement to sell part of its Infusion business to a subsidiary of BTC Health Ltd (ASX:BTC) for $6.3 million.

This will complete the first phase of the Infusion business divestiture. Completion of the sale is subject to certain conditions being satisfied with the sale expected to complete in late May 2019.


Admedus generated $11 million in revenue from its ADAPT® products in 2018, and has steadily been reducing the selling, general and administration costs relative to revenue, as global sales of the ADAPT® product portfolio increases.

The spin-off of Infusion will allow the company to pursue its global growth strategy to focus the business on the commercial growth and development of ADAPT®.

Once the transaction is complete, Admedus’ headcount is expected to reduce by about 19%.

Phase I of the Infusion divestiture is part of the overall company restructuring plans that are underway.

READ: Admedus to spin-off immunotherapies business; shares surge

Admedus managing director and CEO Wayne Paterson said: “The restructure will enable us to improve working capital management and reduce cash burn through reduction in headcount and focus on the ADAPT® portfolio - which is delivering revenue growth and offers significant potential for future value creation as we grow global sales and advance the TAVR device into human clinical trials.”

Quick facts: Admedus Ltd

Price: 4.82 AUD

Market: ASX
Market Cap: $28.49 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...



Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read